Status
Conditions
Treatments
About
This study will assess the ability of MIRODERM to heal difficult diabetic foot ulcers within 12 weeks of treatment.
Full description
The primary objective of this study is to determine the number of successful complete wound closures within 12 weeks of treatment with MIRODERM Fenestrated Biological Wound Matrix. Some secondary objectives of this study include documenting the time course of wound healing and assessing changes in quality of life.
The primary cohort is individuals suffering from a diabetic foot ulcer that has not been healed in the last 3 months and after at least 2 attempts with an advanced biologic. Ulcer will be between 1 and 12 cm squared, less than 5 mm deep, full thickness, below the ankle, and with no exposed bone or tendon. Subjects will be 18 or older, have Type I or II diabetes with adequate vascular profusion. Subjects will be unable to participate if they have osteomyelitis, Charcot foot, a known collagen vascular disease, are on dialyses, are immunocompromised or have an HbA1c level equal to or great than 12%.
This is a single-arm study with no Independent Variables. Descriptive data to be collected will include demographics, pathology and medical history.
Outcome assessments:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
18 years old or older at time of initial visit
Have Type I or Type II diabetes
Have a neuropathic diabetic foot ulcer with the following characteristics:
Be willing and able to maintain required off-loading of affected limb
Be willing and able to perform necessary dressing changes
Have at least one of the following:
Exclusion criteria
53 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal